Mr. Paul Andreola reports

BRISIO INNOVATIONS INVESTS IN IMMUNOPRECISE ANTIBODIES LTD.

Brisio Innovations Inc. has completed an investment in ImmunoPrecise Antibodies Ltd.

The company has subscribed for a convertible note in the principal amount of $97,500. In the event that ImmunoPrecise Antibodies completes a reverse takeover to list on stock exchange (Pubco), the principal amount of the convertible note will be convertible into 650,000 units of Pubco issued at a price of 15 cents per unit.

Each unit will consist of one common share of Pubco and one share purchase warrant. Each Pubco warrant will entitle the company to acquire one additional Pubco share at a price of 30 cents per share for a period of 12 months from the date of issue of the Pubco warrants.

ImmunoPrecise Antibodies is a privately owned Canadian company located in Victoria, B.C., Canada. Its dedication to advancing antibody development has resulted in cutting-edge immunological innovations. ImmunoPrecise Antibodies comprises experienced research and development scientists and encompasses a wide range of distinctive competencies, including innovative technologies required in the production of monoclonal and polyclonal antibodies. Its clients include leading companies in the biotech and pharmaceutical sector, as well as government and academic researchers.

Paul Andreola, president of Brisio Innovations, stated: "We are quite excited with the opportunity to invest in a rapidly growing organization at this early stage. Management have proven themselves to be very skillful in their execution of their business strategy as evidenced by their high-profile clients and high rate of growth. We look forward to their continued performance and further success."

We seek Safe Harbor.